Published in Drug Week, September 9th, 2005
Ciphergen's total revenue was $7.5 million in the second quarter of 2005 as compared to $8.3 million in the second quarter of 2004. Ciphergen's net loss was $9.0 million in the second quarter of 2005 as compared to $13.1 million in the second quarter of 2004.
As of June 30, 2005, the company's cash and investments were $23.5 million. Total long-term debt totaled $28.4 million, of which $28.3 million was convertible debt. On July 22, 2005, Ciphergen entered into a strategic alliance with Quest Diagnostics whereby Quest Diagnostics made a $15...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.